|
[Related PubMed/MEDLINE]
Total Number of Papers: 30
|
|
|
| |
|
[Entries Per Page]
|
|
per page
|
| |
|
Page Control
|
|
|
| Page: of |
|
|
|
| No. |
Year |
Title |
Co-occurring Abbreviation |
| 1 |
2021 |
Comparison of Composite Measure Remission Targets in Psoriatic Arthritis. |
cDAPSA, DAPSA, MDA, PsA, VAS, VLDA |
| 2 |
2021 |
Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. |
DAPSA, GRAPPA, mCPDAI, MDA, mGRACE, PASDAS, PsA, SRMs |
| 3 |
2021 |
Composite Measures for Clinical Trials in Psoriatic Arthritis: Testing Pain and Fatigue Modifications in a UK Multicenter Study. |
DAPSA, GRAPPA, mCPDAI, MDA, mGRACE, PASDAS, PsA, SRMs |
| 4 |
2021 |
Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study. |
DAS28, ES, GRAPPA, PROMs, PsA, sCPDAI, SRM, VAS |
| 5 |
2021 |
Composite Measures for Routine Clinical Practice in Psoriatic Arthritis: Testing of Shortened Versions in a UK Multicenter Study. |
DAS28, ES, GRAPPA, PROMs, PsA, sCPDAI, SRM, VAS |
| 6 |
2021 |
Evaluation and Validation of a Patient-completed Psoriatic Arthritis Flare Questionnaire. |
DAPSA, FLARE, GRAPPA, ICC, PASDAS, PsA |
| 7 |
2021 |
Role of ultrasound for assessment of psoriatic arthritis patients with fibromyalgia. |
DAPSA, FMS, PASDAS, PsA, US |
| 8 |
2020 |
Outcomes of the 2019 GRAPPA Workshop on Continuous Composite Indices for the Assessment of Psoriatic Arthritis and Membership-recommended Next Steps. |
DAPSA, DAS, GRAPPA, PsA |
| 9 |
2019 |
Comparison of disease activity measures in early psoriatic arthritis in usual care. |
DAPSA, DAS28, DEPAR, ES, GRACE, HRQoL, MDA, PASDAS, SRM |
| 10 |
2019 |
Mediterranean diet and Psoriatic Arthritis activity: a multicenter cross-sectional study. |
BMI, DAPSA, MDS, PsA |
| 11 |
2018 |
Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease. |
DAPSA, MDA, OPAL, PASDAS, PsA, TNFi |
| 12 |
2018 |
Gender does not make a difference in "composite psoriatic disease activity index (CPDAI)" in patients with psoriatic arthritis. |
BASDAI, BASFI, CRP, DLQI, ESR, HAQ, PASI, PsA |
| 13 |
2017 |
Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population. |
CASPAR, DAPSA, DAS28, DLQI, ESR, MDA, PASDAS, PASI, PsA, SDAI |
| 14 |
2017 |
The dynamics of response as measured by multiple composite outcome tools in the TIght COntrol of inflammation in early Psoriatic Arthritis (TICOPA) trial. |
AUC, GRAPPA, PASDAS, PsA, SC, TC, TICOPA |
| 15 |
2016 |
Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors. |
anti-TNF, axPsA, BASDAI, CASPAR, DAPSA, MDA, PR |
| 16 |
2016 |
Effect of ethnicity on disease activity and physical function in psoriatic arthritis in a multiethnic Asian population. |
CASPAR, cDAPSA, HAQ, MDA, PsA, SF36 |
| 17 |
2016 |
Management of psoriatic arthritis: Early diagnosis, monitoring of disease severity and cutting edge therapies. |
CASPAR, DAPSA, DMARDs, EULAR, GRAPPA, JAK, PASE, PASQ, PEST, PsA, PsAJAI, TOPAS |
| 18 |
2016 |
The Effect of the Presence of Fibromyalgia on Common Clinical Disease Activity Indices in Patients with Psoriatic Arthritis: A Cross-sectional Study. |
BASDAI, DAPSA, FM, HAQ, LEI, MDA, PsA |
| 19 |
2016 |
Ultrasonographic evaluation in psoriatic arthritis is of major importance in evaluating disease activity. |
DAPSA, MDA, PASDAS, PD, PsA, US |
| 20 |
2015 |
Defining Low Disease Activity States in Psoriatic Arthritis using Novel Composite Disease Instruments. |
MDA, PASDAS |
| 21 |
2014 |
Composite disease activity and responder indices for psoriatic arthritis: a report from the GRAPPA 2013 meeting on development of cutoffs for both disease activity states and response. |
GRACE, PASDAS, PsA |
| 22 |
2014 |
Disease activity in psoriatic arthritis: comparison of the discriminative capacity and construct validity of six composite indices in a real world. |
CRP, DAPSA, ESR, HAQ, MDA, PASDAS, PASI, SDAI |
| 23 |
2014 |
Remission criteria and activity indices in psoriatic arthritis. |
ACR/EULAR, CDAI, CI, DAPSA, DAS28, PASE, PsA, RA, SDAI |
| 24 |
2014 |
Serum YKL-40 in psoriasis with and without arthritis; correlation with disease activity and high-resolution power Doppler ultrasonographic joint findings. |
CDUS, PDUS, PsA, TJS |
| 25 |
2013 |
Comparison of composite measures of disease activity in psoriatic arthritis using data from an interventional study with golimumab. |
AMDF, DAPSA, DAS28, PASDAS |
| 26 |
2013 |
Disparity between ultrasound and clinical findings in psoriatic arthritis. |
CPDAI-JED, DAPSA, MDA, MUDA, PsA |
| 27 |
2012 |
Measures of psoriatic arthritis: Tender and Swollen Joint Assessment, Psoriasis Area and Severity Index (PASI), Nail Psoriasis Severity Index (NAPSI), Modified Nail Psoriasis Severity Index (mNAPSI), Mander/Newcastle Enthesitis Index (MEI), Leeds Enthesitis Index (LEI), Spondyloarthritis Research Consortium of Canada (SPARCC), Maastricht Ankylosing Spondylitis Enthesis Score (MASES), Leeds Dactylitis Index (LDI), Patient Global for Psoriatic Arthritis, Dermatology Life Quality Index (DLQI), Psoriatic Arthri |
DAPSA, DLQI, FACIT-F, LDI, LEI, MASES, MEI, mNAPSI, NAPSI, PASI, PsAJAI, PsAQoL, PsARC, SPARCC |
| 28 |
2012 |
The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project). |
AUC, DAPSA, PsA, ROC |
| 29 |
2010 |
Application of the GRAPPA psoriatic arthritis treatment recommendations in clinical practice. |
GRAPPA |
| 30 |
2010 |
Development of a preliminary composite disease activity index in psoriatic arthritis. |
--- |
|
A Search Service for Abbreviation / Long Form
